Database on cancer-related genetic variations has been released by National Cancer Institute.

Many of the recently approved cancer drugs are designed to specifically block selected pathways that the cancer cells use to grow and reproduce. Before the drugs are administered, patients should be tested for the specific genetic mutations that would make the drug more likely to be beneficial to them.
For instance, the melanoma drug “Zelboraf,” sold by Roche, is designed to work by targeting a specific genetic mutation found commonly in about half of all melanomas. Pfizer Inc's drug Xalkori, targets a mutation in the ALK gene, and it works in about 4-5 percent of lung cancer patients. The database is expected to encourage more such approaches to enable us to take a giant leap closer towards personalized medicine.
Source-Medindia